Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 28

1.

Silymarin for HCV infection.

Polyak SJ, Oberlies NH, Pécheur EI, Dahari H, Ferenci P, Pawlotsky JM.

Antivir Ther. 2013;18(2):141-7. doi: 10.3851/IMP2402. Epub 2012 Sep 25. Review.

2.

Hepatitis C therapy in non-genotype 1 patients: the near future.

Wartelle-Bladou C, Le Folgoc G, Bourlière M, Lecomte L.

J Viral Hepat. 2012 Aug;19(8):525-36. doi: 10.1111/j.1365-2893.2012.01634.x. Review.

PMID:
22762136
3.

Complementary and alternative medicines in prostate cancer: from bench to bedside?

Klempner SJ, Bubley G.

Oncologist. 2012;17(6):830-7. doi: 10.1634/theoncologist.2012-0094. Epub 2012 May 22. Review.

4.

Potential renoprotective effects of silymarin against nephrotoxic drugs: a review of literature.

Dashti-Khavidaki S, Shahbazi F, Khalili H, Lessan-Pezeshki M.

J Pharm Pharm Sci. 2012;15(1):112-23. Review.

5.

Legalon® SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning.

Mengs U, Pohl RT, Mitchell T.

Curr Pharm Biotechnol. 2012 Aug;13(10):1964-70. Review.

6.

Immunosuppression, liver injury and post-transplant HCV recurrence.

Ciesek S, Wedemeyer H.

J Viral Hepat. 2012 Jan;19(1):1-8. doi: 10.1111/j.1365-2893.2011.01548.x. Epub 2011 Nov 7. Review.

PMID:
22187942
7.

Reassessing bioavailability of silymarin.

Javed S, Kohli K, Ali M.

Altern Med Rev. 2011 Sep;16(3):239-49. Review.

8.

Silybin and the liver: from basic research to clinical practice.

Loguercio C, Festi D.

World J Gastroenterol. 2011 May 14;17(18):2288-301. doi: 10.3748/wjg.v17.i18.2288. Review.

9.

Silymarin in the prevention and treatment of liver diseases and primary liver cancer.

Féher J, Lengyel G.

Curr Pharm Biotechnol. 2012 Jan;13(1):210-7. Review.

PMID:
21466434
10.

Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer.

Shanmugam MK, Kannaiyan R, Sethi G.

Nutr Cancer. 2011;63(2):161-73. doi: 10.1080/01635581.2011.523502. Review.

PMID:
21294053
11.

Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer.

Deep G, Agarwal R.

Cancer Metastasis Rev. 2010 Sep;29(3):447-63. doi: 10.1007/s10555-010-9237-0. Review.

12.

Milk thistle in liver diseases: past, present, future.

Abenavoli L, Capasso R, Milic N, Capasso F.

Phytother Res. 2010 Oct;24(10):1423-32. doi: 10.1002/ptr.3207. Review.

PMID:
20564545
14.

Patented bioavailability enhancement techniques of silymarin.

Javed S, Kohli K, Ali M.

Recent Pat Drug Deliv Formul. 2010 Jun;4(2):145-52. Review.

PMID:
20156178
15.

Targeting silibinin in the antiproliferative pathway.

Li L, Zeng J, Gao Y, He D.

Expert Opin Investig Drugs. 2010 Feb;19(2):243-55. doi: 10.1517/13543780903533631. Review.

PMID:
20047507
16.

Silybin-phosphatidylcholine complex. Monograph.

[No authors listed]

Altern Med Rev. 2009 Dec;14(4):385-90. Review. No abstract available.

17.

Silibinin--a promising new treatment for cancer.

Cheung CW, Gibbons N, Johnson DW, Nicol DL.

Anticancer Agents Med Chem. 2010 Mar;10(3):186-95. Review.

PMID:
20015009
19.

Cosmeceuticals and silibinin.

Singh RP, Agarwal R.

Clin Dermatol. 2009 Sep-Oct;27(5):479-84. doi: 10.1016/j.clindermatol.2009.05.012. Review.

20.

Photochemoprevention of cutaneous neoplasia through natural products.

Filip A, Clichici S, Daicoviciu D, Adriana M, Postescu ID, Perde-Schrepler M, Olteanu D.

Exp Oncol. 2009 Mar;31(1):9-15. Review.

PMID:
19300410
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk